| Pharmacogenetics of pregnancy‐induced changes in efavirenz pharmacokinetics A Olagunju, O Bolaji, A Amara, L Else, O Okafor, E Adejuyigbe, J Oyigboja, ... Clinical Pharmacology & Therapeutics 97 (3), 298-306, 2015 | 54 | 2015 |
| Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS A Olagunju, OO Bolaji, A Amara, C Waitt, L Else, J Soyinka, B Adeagbo, ... Journal of Antimicrobial Chemotherapy 70 (2), 555-61, 2015 | 48 | 2015 |
| Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study A Olagunju, O Bolaji, A Amara, C Waitt, L Else, E Adejuyigbe, M Siccardi, ... Clinical Infectious Diseases 61 (3), 453-463, 2015 | 45 | 2015 |
| Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother–infant pairs C Waitt, A Olagunju, S Nakalema, I Kyohaire, A Owen, M Lamorde, ... Journal of Antimicrobial Chemotherapy 73 (4), 1013-1019, 2018 | 42 | 2018 |
| Optimizing pharmacology studies in pregnant and lactating women using lessons from HIV: a consensus statement AC Eke, A Olagunju, J Momper, M Penazzato, EJ Abrams, BM Best, ... Clinical Pharmacology & Therapeutics 110 (1), 36-48, 2021 | 38 | 2021 |
| The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children A Bienczak, A Cook, L Wiesner, A Olagunju, V Mulenga, C Kityo, ... British Journal of Clinical Pharmacology 82 (1), 185-198, 2016 | 38 | 2016 |
| Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz M Siccardi, A Olagunju, K Seden, F Ebrahimjee, S Rannard, D Back, ... In Silico Pharmacology 1, 1-8, 2013 | 38 | 2013 |
| Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding A Olagunju, A Owen, TR Cressey Pharmacogenomics 13 (13), 1501-1522, 2012 | 37 | 2012 |
| A Validated Method for Quantification of Efavirenz in Dried Blood Spots (DBS) using HPLC-MS/MS. AB Amara, LJ Else, J Tjia, A Olagunju, RL Puls, S Khoo, DJ Back Therapeutic drug monitoring 37 (2), 220-8, 2015 | 36* | 2015 |
| The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine M Neary, M Lamorde, A Olagunju, KM Darin, C Merry, P Byakika‐Kibwika, ... Clinical Pharmacology & Therapeutics 102 (3), 529-536, 2017 | 35 | 2017 |
| CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults A Olagunju, A Schipani, M Siccardi, D Egan, S Khoo, D Back, A Owen Pharmacogenetics and Genomics, 2014 | 33 | 2014 |
| Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots A Olagunju, A Amara, C Waitt, L Else, SD Penchala, O Bolaji, J Soyinka, ... Journal of Antimicrobial Chemotherapy 70 (10), 2816-2822, 2015 | 29 | 2015 |
| Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk … C Waitt, SD Penchala, A Olagunju, A Amara, L Else, M Lamorde, S Khoo Journal of Chromatography B 1060, 300-307, 2017 | 28 | 2017 |
| Innovative approaches for pharmacology studies in pregnant and lactating women: a viewpoint and lessons from HIV AC Eke, A Olagunju, BM Best, M Mirochnick, JD Momper, E Abrams, ... Clinical pharmacokinetics 59, 1185-1194, 2020 | 22 | 2020 |
| Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies SA Atoyebi, RKR Rajoli, E Adejuyigbe, A Owen, O Bolaji, M Siccardi, ... European Journal of Pharmaceutical Sciences 140, 105068, 2019 | 20 | 2019 |
| Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding A Olagunju, RKR Rajoli, SA Atoyebi, S Khoo, A Owen, M Siccardi AAS Open Research 1, 16, 2018 | 20 | 2018 |
| A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine J Francis, SP Zvada, P Denti, M Hatherill, S Charalambous, S Mungofa, ... Antimicrobial agents and chemotherapy 63 (4), 10.1128/aac. 01964-18, 2019 | 19 | 2019 |
| Pregnancy affects nevirapine pharmacokinetics: evidence from a: CYP2B6: genotype-guided observational study A Olagunju, O Bolaji, M Neary, D Back, S Khoo, A Owen Pharmacogenetics and Genomics 26 (8), 381-389, 2016 | 17 | 2016 |
| CYP2B6 516G> T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients A Olagunju, M Siccardi, A Amara, D Jevtovic, J Kusic, A Owen, G Dragovic Therapeutic drug monitoring 36 (6), 734-738, 2014 | 17 | 2014 |
| Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria JN Nwogu, M Gandhi, A Owen, SH Khoo, B Taiwo, A Olagunju, B Berzins, ... Aids 35 (12), 1919-1927, 2021 | 16 | 2021 |
Andrew OwenUniversity of Liverpool在 liv.ac.uk 的电子邮件经过验证
